Visit @theaacr.bsky.social Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest groundbreaking research published in the Journals.

The 🚨 OncoAlert TOP 10 — #WCLC26 🌐

👉Advanced #SCLC & #Mesothelioma 🇰🇷

We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Small Cell #LungCancer ( #SCLC ) and Mesothelioma🫁

That’s a wrap on the GLCC Members’ Meeting.
Our shared workplan for the next 12 months is now agreed, and we’ll be posting updates here — and on our new website coming soon.

Grateful to everyone who strengthens this global #lungcancer advocacy network.
See you at #WCLC26 and in Denver next year.

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented

MO15.05 Expression and Prognostic Impact of B7-H3 in Patients With Extensive-Stage Small-Cell Lung Cancer

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented

MO15.02 A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented

MO15.04 First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstracts to be presented Next week

OA05.02 Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Autologous CAR-T Cell Therapy, in Subjects With Relapsed or Refractory #SCLC or LCNEC

2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology

Thank you @europeanrespsoc.bsky.social for an excellent #ERSCongress2026 in Barcelona.

We presented 2 abstracts, contributed to discussions on #lungcancer & made new connections across respiratory health.

Read our round-up:
lungcancereurope.eu/news/lung-ca...

Now on to #WCLC26 in Seoul ✈️ #LCSM

Want to know what to look for at #WCLC26? Sign up for exclusive insights from @drcamidge.bsky.social, of @cumedicalschool.bsky.social, and @lungoncdoc.bsky.social, of @mdanderson.bsky.social! @iaslc.bsky.social #lcsm #oncology

See the full preview on our site: www.onclive.com/view/camidge...

Join Foundation Medicine for our “Booth Talk Series” at #WCLC26. Hear from our team of experts on the latest advancements that are driving innovation in precision diagnostics and lung cancer treatment. Review the session topics below. Learn about Foundation Medicine and more: spkl.io/633237utKb

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week

OA12.01 — Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

✅ Compelling single-arm activity with tolerable safety in a heavily pretreated population.

The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week

MO06.01 — NAUTIKA1: Primary Analysis of Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK+ NSCLC

⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! Not Speaker Slides

The OncoAlert #WCLC26 Top 10 Deep Dive!

OA09.03 — A Phase 2 Study of JS207, a PD-1/VEGF Bispecific Antibody, Plus Chemotherapy in Patients With Unresectable Stage III NSCLC

⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! Not Speaker Slides

The OncoAlert #WCLC26 Top 10 Deep Dive

OA09.02 — ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer

⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! Not Speaker Slides

The OncoAlert #WCLC26 Top 10 Deep Dive!

OA04.04 — Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data

⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! Not Speaker Slides

#WCLC26 Top 10 Deep Dive! Abstract to be presented Next week

OA04.02Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC: MDT-BRIDGE Primary Analysis

⭐️ These Slides were created based on publicly released #WCLC26 abstracts and Not Speaker Slides

The OncoAlert #WCLC26 Top 10 Deep Dive

OA04.01A Phase III Randomized Multicenter Trial of Adjuvant Gefitinib Plus Chemotherapy Versus Chemotherapy in EGFR-Mutant NSCLC

⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! These are not Speaker Slides